Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Clear Cell Adenocarcinoma

Explore clinical trials studying Fallopian Tube Clear Cell Adenocarcinoma. Study availability and eligibility vary by location and protocol.

20 public trials 3 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Clear Cell Adenocarcinoma trial results

Completed

Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02713386

Conditions
Adnexal Diseases, FIGO Stage III Ovarian Cancer 2014, FIGO Stage IIIA Ovarian Cancer 2014, +35 more
Locations
  • CTCA at Western Regional Medical Center Goodyear, Arizona, United States
  • Sutter Auburn Faith Hospital Auburn, California, United States
  • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Sutter Roseville Medical Center Roseville, California, United States
View all 110 locations
View Trial Details
Completed

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

NCT02020707

Conditions
Cervical Adenocarcinoma, Cervical Adenosarcoma, Cervical Adenosquamous Carcinoma, +45 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Mayo Clinic in Rochester Rochester, Minnesota, United States
View Trial Details
Completed

First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT01097746

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • M D Anderson Cancer Center Houston, Texas, United States
  • MD Anderson Regional Care Center-Katy Houston, Texas, United States
  • MD Anderson Regional Care Center-Bay Area Nassau Bay, Texas, United States
  • MD Anderson Regional Care Center-Sugar Land Sugar Land, Texas, United States
View Trial Details
Completed

Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00888615

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +39 more
Locations
  • Saint Joseph's Hospital and Medical Center Phoenix, Arizona, United States
  • John Muir Medical Center-Concord Campus Concord, California, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • University of California San Diego San Diego, California, United States
View all 163 locations
View Trial Details
Completed

Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

NCT00989651

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +59 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of Colorado Hospital Aurora, Colorado, United States
  • Augusta University Medical Center Augusta, Georgia, United States
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
View all 23 locations
View Trial Details
Completed

Cabozantinib-S-Malate in Treating Patients With Recurrent or Progressive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02315430

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +19 more
Locations
  • Anchorage Radiation Therapy Center Anchorage, Alaska, United States
  • Alaska Breast Care and Surgery LLC Anchorage, Alaska, United States
  • Alaska Oncology and Hematology LLC Anchorage, Alaska, United States
  • Alaska Regional Hospital Anchorage, Alaska, United States
View all 410 locations
View Trial Details
Completed

Propranolol Hydrochloride and Chemotherapy in Treating Patients With Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01504126

Conditions
Adnexal Diseases, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Diseases, +44 more
Locations
  • Banner MD Anderson Cancer Center Gilbert, Arizona, United States
  • Lyndon Baines Johnson General Hospital Houston, Texas, United States
  • M D Anderson Cancer Center Houston, Texas, United States
  • The Woman's Hospital of Texas Houston, Texas, United States
View Trial Details
Completed

Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT01074411

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +41 more
Locations
  • Hartford Hospital Hartford, Connecticut, United States
  • The Hospital of Central Connecticut New Britain, Connecticut, United States
  • University of Iowa/Holden Comprehensive Cancer Center Iowa City, Iowa, United States
  • Washington University School of Medicine St Louis, Missouri, United States
View all 14 locations
View Trial Details
Completed

Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

NCT00262847

Conditions
Adnexal Diseases, Brenner Tumor, Endocrine Gland Neoplasms, +48 more
Locations
  • Northeast Alabama Regional Medical Center Anniston, Alabama, United States
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Clearview Cancer Institute Huntsville, Alabama, United States
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
View all 632 locations
View Trial Details

Related conditions